Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

rrCLL × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 2970 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2485 Lymphoma, Non-Hodgkin 2257 Leukemia, Lymphocytic, Chronic, B-Cell 1985 Lymphoma, Follicular 1829 Lymphoma, Large B-Cell, Diffuse 1779 Leukemia 1335 Hodgkin Disease 1289 Lymphoma, Mantle-Cell 1188 Leukemia, Myeloid, Acute 971 Burkitt Lymphoma 950 Multiple Myeloma 862 Lymphoma, B-Cell, Marginal Zone 847 Recurrence 835 Lymphoma, B-Cell 744 Myelodysplastic Syndromes 679 Neoplasms 592 Lymphoma, T-Cell, Cutaneous 541 Waldenstrom Macroglobulinemia 510 Lymphoma, Large-Cell, Immunoblastic 490 Mycosis Fungoides 438 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 411 Lymphoma, Large-Cell, Anaplastic 390 Sezary Syndrome 364 Lymphoma, T-Cell, Peripheral 349 Hematologic Neoplasms 349 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 334 Myeloproliferative Disorders 328 Neoplasms, Plasma Cell 309 Blast Crisis 284

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡